CAMBRIDGE, Mass., August 9, 2016 -- Mersana Therapeutics, Inc. today announced that Anna Protopapas, President and Chief Executive Officer, will present at the 2016 Wedbush PacGrow Healthcare Conference at the Le Parker Meridien on Tuesday, August 16, 2016, at 1:55 p.m. ET.

About Mersana Therapeutics                                         

Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's product candidates XMT-1522 and XMT-1536 have the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.

###

Media Contact
6 Degrees
Tony Plohoros
tplohoros@6degreespr.com
(908) 591-2839

Investor Contact
Stern Investor Relations, Inc.
Jesse Baumgartner
Jesse@sternir.com
(212) 362-1200